Coloplast Management

Management criteria checks 4/4

Coloplast's CEO is Kristian Villumsen, appointed in Dec 2018, has a tenure of 5.92 years. total yearly compensation is DKK22.00M, comprised of 55.9% salary and 44.1% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $12.72M. The average tenure of the management team and the board of directors is 5.9 years and 6.8 years respectively.

Key information

Kristian Villumsen

Chief executive officer

DKK 22.0m

Total compensation

CEO salary percentage	55.9%
CEO tenure	5.9yrs
CEO ownership	0.04%
Management average tenure	5.9yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kristian Villumsen's remuneration changed compared to Coloplast's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	DKK 22m	DKK 12m	DKK 5b
Jun 30 2024	n/a	n/a	DKK 5b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	n/a	n/a	DKK 5b
Sep 30 2023	DKK 23m	DKK 12m	DKK 5b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b

Compensation vs Market: Kristian's total compensation ($USD3.10M) is below average for companies of similar size in the US market ($USD12.74M).

Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.

CEO

Kristian Villumsen (54 yo)

5.9yrs

Tenure

DKK 22,000,000

Compensation

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kristian Villumsen	President & CEO	5.9yrs	DKK 22.00m	0.045% $ 12.7m
Anders Lonning-Skovgaard	Executive VP & CFO	10.3yrs	DKK 11.30m	0.0012% $ 333.7k
Allan Rasmussen	Executive Vice President of Global Operations	10.3yrs	DKK 9.90m	0.011% $ 3.2m
Nicolai Andersen	Executive Vice President of Chronic Care	no data	DKK 9.50m	no data
Paul Marcun	Executive Vice President of Growth	5.8yrs	DKK 11.50m	0.014% $ 3.8m
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000020% $ 5.7k
Aleksandra Dimovska	Vice President of Investor Relations	no data	no data	no data
Dennis Kaysen	Vice President of Corporate Communications	no data	no data	no data
Dorthe Ronnau	Executive Vice President of People & Culture	2.8yrs	no data	no data
Alain Morvan	Senior Vice President of Sales Europe	12.6yrs	no data	no data
Caroline Rosenstand	Executive Vice President of Voice & Respiratory Care	no data	no data	no data
Rasmus Møller	Senior Vice President of Wound & Skin Care	4.2yrs	no data	no data

5.9yrs

Average Tenure

55yo

Average Age

Experienced Management: CLPB.F's management team is seasoned and experienced (5.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Barfod	Senior Controller & Employees Representative Director	18.8yrs	DKK 450.00k	0.000020% $ 5.7k
Carsten Hellmann	Independent Director	6.9yrs	DKK 690.00k	0.0027% $ 755.0k
Lars Rasmussen	Independent Chairman of the Board	5.9yrs	DKK 1.84m	0.0054% $ 1.5m
Niels Louis-Hansen	Deputy Chairman	56.8yrs	DKK 938.00k	1.93% $ 546.6m
Marianne Wiinholt	Independent Director	3.9yrs	DKK 880.00k	0.00022% $ 62.2k
Jette Nygaard-Andersen	Independent Director	8.9yrs	DKK 600.00k	no data
Nikolaj Gundersen	Employees Representative Director	6.8yrs	DKK 450.00k	no data
Roland Pedersen	Employees Representative Director	6.8yrs	DKK 450.00k	0.00072% $ 203.6k
Annette Bruls	Independent Director	2.9yrs	DKK 600.00k	no data

6.8yrs

Average Tenure

59yo

Average Age

Experienced Board: CLPB.F's board of directors are considered experienced (6.8 years average tenure).

Coloplast Management

Management criteria checks 4/4

Key information

Recent management updates

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast Announces Executive Changes

Contraline Names Yelena Tropsha as CTO

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age